牛牛AI助理已提取核心訊息
On December 21, 2023, Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by a group of related investment entities and an individual, collectively referred to as the Reporting Persons. These include Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh, a U.S. citizen. The filing indicates that these entities and Mr. Walsh collectively hold a significant number of ordinary shares and American Depositary Shares (ADSs) of Biodexa Pharmaceuticals, which represent a 9.9% and 8.1% ownership stake respectively. The shares include those issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership blocker, preventing the Reporting Persons from exceeding this ownership threshold. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
On December 21, 2023, Biodexa Pharmaceuticals PLC, a company listed on The Nasdaq Capital Market under the symbol BDRX, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by a group of related investment entities and an individual, collectively referred to as the Reporting Persons. These include Cavalry Fund I LP, Cavalry Fund I Management LLC, Cavalry Investment Fund LP, Cavalry Fund GP, LLC, and Thomas Walsh, a U.S. citizen. The filing indicates that these entities and Mr. Walsh collectively hold a significant number of ordinary shares and American Depositary Shares (ADSs) of Biodexa Pharmaceuticals, which represent a 9.9% and 8.1% ownership stake respectively. The shares include those issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership blocker, preventing the Reporting Persons from exceeding this ownership threshold. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
2023年12月21日，在納斯達克資本市場上市的股票代碼爲BDRX的公司Biodexa Pharmicals PLC成爲向美國證券交易委員會提交的附表13G文件的主體。該申報是由一組相關的投資實體和一名個人提交的，統稱爲 “申報人”。其中包括騎兵基金I LP、Cavalry Fund I Management LLC、Cavalry Investment Fund LP、Cavalry Fund GP, LLC和美國公民托馬斯·沃爾什。文件顯示，這些實體和沃爾什先生共同持有Biodexa Pharmicals的大量普通股和美國存托股份（ADS），分別佔9.9％和8.1％的所有權。這些股票包括在行使認股權證時可發行的股票，這些認股權證受9.99％的受益所有權封鎖，以防止申報人超過該所有權門檻。該文件稱，收購這些股份不是爲了改變或影響Biodexa Pharmicals的控制權。
2023年12月21日，在納斯達克資本市場上市的股票代碼爲BDRX的公司Biodexa Pharmicals PLC成爲向美國證券交易委員會提交的附表13G文件的主體。該申報是由一組相關的投資實體和一名個人提交的，統稱爲 “申報人”。其中包括騎兵基金I LP、Cavalry Fund I Management LLC、Cavalry Investment Fund LP、Cavalry Fund GP, LLC和美國公民托馬斯·沃爾什。文件顯示，這些實體和沃爾什先生共同持有Biodexa Pharmicals的大量普通股和美國存托股份（ADS），分別佔9.9％和8.1％的所有權。這些股票包括在行使認股權證時可發行的股票，這些認股權證受9.99％的受益所有權封鎖，以防止申報人超過該所有權門檻。該文件稱，收購這些股份不是爲了改變或影響Biodexa Pharmicals的控制權。
有用
沒用